New hope for tough leukemia: drug cocktail targets resistant cancer
NCT ID NCT05222984
First seen Apr 21, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in people with acute myeloid leukemia that has returned or stopped responding after prior treatment with venetoclax. The main goal is to find the safest dose and understand side effects. About 17 adults and teens aged 16 and older are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.